HCW Biologics Inc (HCWB)

Form D - Notice of Exempt Offering of Securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

DENVER, May 22, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – The biotechnology sector continues attracting speculative capital as...

Form 8-K - Current report

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

MIRAMAR, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”...

Form POS AM - Post-Effective amendments for registration statement

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”...

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates...